Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models-MedSci.cn

Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models

Nagashima, T; Yoshinari, T; Nishizono, Y; Tasaki, M; Inamura, K; Ishioka, H; Suzuki, A; Osaki, F; Yamanaka, Y; Hayakawa, M

CANCER RESEARCH, 2023; 83 (7):

科室
- - 订阅+
  - 更多科室
工具
服务